Hutchmed Licenses KRAS-EGFR Dual-Target ADC to GSK with $110M Upfront Payment
nashnova research
Hutchmed granted GSK global rights (ex-Greater China) to its first-in-class dual-target cancer drug HMPL-A830, collecting $110 million upfront with milestones up to $1.295 billion — but the deal's real value hinges on Phase I data still to come.
Who gets what in this deal?
Hutchmed (和黄医药, SEHK: 00013) hands GSK the rights to develop and commercialize HMPL-A830 everywhere outside Greater China.
GSK pays $110 million upfront, with development, regulatory, and commercial milestones totaling up to $1.295 billion, plus tiered royalties on net sales.
This means → Hutchmed has secured a potential $1.4 billion+ package for a drug that has not yet entered the clinic — the upfront cash is locked in, but the rest is a series of data-dependent IOUs.
Why is GSK willing to pay?
HMPL-A830 is an ATTC — an antibody-targeted conjugate that straps a tumor-killing "warhead" onto an antibody that homes in on cancer cells, so the drug attacks tumors while largely sparing healthy tissue.
What makes it distinctive is dual targeting: the antibody locks onto EGFR — a receptor commonly found on tumor surfaces — while the warhead is a highly selective KRAS inhibitor. In plain terms = one mechanism finds the tumor, the other shuts down its growth engine — two layers of precision in a single molecule.
This reflects a clear gap in existing KRAS-only therapies on safety and durability — GSK is betting that hitting two targets beats hitting one.
How will the clinical work be split?
Hutchmed runs the global Phase I program, expected to start in H2 2026.
After Phase I, GSK takes over all subsequent clinical development and commercialization outside Greater China.
The initial focus is colorectal, pancreatic, and lung cancer — the three tumor types with the highest rates of KRAS mutations and the most urgent unmet need.
Where is the key validation point?
The deal's central uncertainty is Phase I data: whether HMPL-A830 can demonstrate efficacy and tolerability superior to existing single-target KRAS therapies in these three cancers.
This means → whether milestone payments convert from paper figures into real cash depends entirely on clinical results — $110 million is banked; the remaining ~$1.2 billion is still an unfulfilled promise.
Hutchmed's acting CEO Eddy Zheng called the partnership "an important step in maximizing the drug's clinical potential"; GSK's oncology R&D head Hesham Abdullah said the dual-target mechanism "has the potential to meaningfully improve current standard of care."
市场有风险，内容仅供研究参考，不构成投资建议。